These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 2033444)
41. Specific genes expressed in association with progesterone receptors in meningioma. Claus EB; Park PJ; Carroll R; Chan J; Black PM Cancer Res; 2008 Jan; 68(1):314-22. PubMed ID: 18172325 [TBL] [Abstract][Full Text] [Related]
42. New prospects for management and treatment of inoperable and recurrent skull base meningiomas. Johnson MD; Sade B; Milano MT; Lee JH; Toms SA J Neurooncol; 2008 Jan; 86(1):109-22. PubMed ID: 17624496 [TBL] [Abstract][Full Text] [Related]
43. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Goyeneche AA; Carón RW; Telleria CM Clin Cancer Res; 2007 Jun; 13(11):3370-9. PubMed ID: 17545545 [TBL] [Abstract][Full Text] [Related]
44. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. Korhonen K; Salminen T; Raitanen J; Auvinen A; Isola J; Haapasalo H J Neurooncol; 2006 Oct; 80(1):1-7. PubMed ID: 16703453 [TBL] [Abstract][Full Text] [Related]
45. Salvage chemotherapy with CPT-11 for recurrent meningioma. Chamberlain MC; Tsao-Wei DD; Groshen S J Neurooncol; 2006 Jul; 78(3):271-6. PubMed ID: 16628476 [TBL] [Abstract][Full Text] [Related]
46. Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. Hahn BM; Schrell UM; Sauer R; Fahlbusch R; Ganslandt O; Grabenbauer GG J Neurooncol; 2005 Sep; 74(2):157-65. PubMed ID: 16193387 [TBL] [Abstract][Full Text] [Related]
47. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Wolfsberger S; Doostkam S; Boecher-Schwarz HG; Roessler K; van Trotsenburg M; Hainfellner JA; Knosp E Neurosurg Rev; 2004 Oct; 27(4):238-45. PubMed ID: 15168138 [TBL] [Abstract][Full Text] [Related]
49. Non-resectable slow-growing meningiomas treated by hydroxyurea. Loven D; Hardoff R; Sever ZB; Steinmetz AP; Gornish M; Rappaport ZH; Fenig E; Ram Z; Sulkes A J Neurooncol; 2004; 67(1-2):221-6. PubMed ID: 15072471 [TBL] [Abstract][Full Text] [Related]
50. A benefit-risk assessment of medical treatment for uterine leiomyomas. De Leo V; Morgante G; La Marca A; Musacchio MC; Sorace M; Cavicchioli C; Petraglia F Drug Saf; 2002; 25(11):759-79. PubMed ID: 12222988 [TBL] [Abstract][Full Text] [Related]
51. Proven and potential clinical applications of mifpristone (RU486). Spitz IM Rev Endocr Metab Disord; 2002 Sep; 3(3):267-75. PubMed ID: 12215721 [No Abstract] [Full Text] [Related]
52. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. Belanoff JK; Jurik J; Schatzberg LD; DeBattista C; Schatzberg AF J Mol Neurosci; 2002; 19(1-2):201-6. PubMed ID: 12212781 [TBL] [Abstract][Full Text] [Related]
53. Hydroxyurea chemotherapy for unresectable or residual meningioma. Newton HB; Slivka MA; Stevens C J Neurooncol; 2000 Sep; 49(2):165-70. PubMed ID: 11206012 [TBL] [Abstract][Full Text] [Related]
59. Crosstalk between normal and tumoral brain cells. Effect on sex steroid metabolism. Melcangi RC; Cavarretta I; Magnaghi V; Ballabio M; Martini L; Motta M Endocrine; 1998 Feb; 8(1):65-71. PubMed ID: 9666347 [TBL] [Abstract][Full Text] [Related]
60. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. Dziuk TW; Woo S; Butler EB; Thornby J; Grossman R; Dennis WS; Lu H; Carpenter LS; Chiu JK J Neurooncol; 1998 Apr; 37(2):177-88. PubMed ID: 9524097 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]